Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lunai BioworksSTU:2Q5 26 PS Ratio is 1,394.67 as of Jul. 29, 2026, which is 106% above its 10-year median of 675.90. GuruFocus rates STU:2Q5 with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 929 Biotechnology companies, Lunai Bioworks ranks worse than 92.47% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lunai Bioworks's share price is €8.368.
Lunai Bioworks's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.01. Hence, Lunai Bioworks's PS Ratio for today is 1,394.67.
The historical rank and industry rank for Lunai Bioworks's PS Ratio or its related term are showing as below:
STU:2Q5'
s PS Ratio Range Over the Past 10 Years
Min: 4.09 Med: 675.9 Max: 2453.19
Current: 320
During the past 13 years, Lunai Bioworks's highest PS Ratio was 2453.19. The lowest was 4.09. And the median was 675.90.
STU:2Q5's PS Ratio is ranked worse than 92.47% of 929
companies
in the Biotechnology industry
Industry Median: 9
vs STU:2Q5: 320.00
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lunai Bioworks PS Ratio Related Terms
Lunai Bioworks PS Ratio Historical Data
* Premium members only.
The historical data trend for Lunai Bioworks's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lunai Bioworks's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lunai Bioworks PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lunai Bioworks's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lunai Bioworks's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lunai Bioworks's Share Price of today is €8.368. Lunai Bioworks's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lunai Bioworks (STU:2Q5) has a PS Ratio of 1,394.67 as of Jul. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lunai Bioworks and its competitors. This is 106% above median its historical median of 675.90. Over the past decade, Lunai Bioworks' PS Ratio has ranged from 4.09 to 2,453.19. According to the industry distribution chart, Lunai Bioworks ranks #859 out of 929 companies in the Biotechnology industry, placing it in the top 92.5%.
Is Lunai Bioworks' PS Ratio too high?
Lunai Bioworks' current PS Ratio of 1,394.67 is 106% above median its 10-year median of 675.90. Over the past 10 years, this metric has ranged from a low of 4.09 to a high of 2,453.19. The Biotechnology industry median PS Ratio is 9.00. Lunai Bioworks' value of 1,394.67 is 15396.3% above this industry median. Based on the distribution chart, Lunai Bioworks ranks #859 out of 929 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lunai Bioworks has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Lunai Bioworks' PS Ratio compare to BCLI and BIVI?
According to the Biotechnology industry distribution chart, Lunai Bioworks ranks #859 out of 929 companies for PS Ratio. This places Lunai Bioworks in the lower half of its industry. The industry median PS Ratio is 9.00. Lunai Bioworks' value of 1,394.67 is 15396.3% above this benchmark. Historically, Lunai Bioworks' own PS Ratio has ranged from 4.09 to 2,453.19 over the past decade. While the company's 10-year median is 675.90 vs. the industry median of 9.00, Lunai Bioworks has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.00, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lunai Bioworks's current PS Ratio of 1,394.67 is 15396.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lunai Bioworks and its competitors. For the Biotechnology industry, the median PS Ratio is 9.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lunai Bioworks's current PS Ratio is 1,394.67, which is 106% above median its own 10-year median of 675.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lunai Bioworks stock overvalued right now?
Lunai Bioworks (STU:2Q5) has a current PS Ratio of 1,394.67. The current PS Ratio is 1,394.67, which is 106% above median its 10-year median of 675.90 and 15396.3% above the Biotechnology industry median of 9.00. Lunai Bioworks' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lunai Bioworks (STU:2Q5), the current PS Ratio is 1,394.67 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
26GF Score
Get the complete analysis for STU:2Q5
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2Q5 has been successfully added to your 
